Establishing an immune correlate of protection for Nipah virus in nonhuman primates

V. H. Leyva-Grado; D. Promeneur; K. N. Agans; G. G. Lazaro; V. Borisevich; D. J. Deer; A. Luckay; M. Egan; A. S. Dimitrov; B. Small; C. C. Broder; R. W. Cross; S. Hamm; T. W. Geisbert

doi:10.1038/s41541-024-01036-2

Establishing an immune correlate of protection for Nipah virus in nonhuman primates

V. H. Leyva-Grado, D. Promeneur, K. N. Agans, G. G. Lazaro, V. Borisevich, D. J. Deer, A. Luckay, M. Egan, A. S. Dimitrov, B. Small, C. C. Broder, R. W. Cross, S. Hamm, T. W. Geisbert

Microbiology And Immunology

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

Original language	English (US)
Article number	244
Journal	npj Vaccines
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41541-024-01036-2
State	Published - Dec 2024

ASJC Scopus subject areas

Immunology
Pharmacology
Infectious Diseases
Pharmacology (medical)

Access to Document

10.1038/s41541-024-01036-2

Cite this

@article{bed14cfea1b14639b0f3be18bd42a1fa,

title = "Establishing an immune correlate of protection for Nipah virus in nonhuman primates",

abstract = "The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.",

author = "Leyva-Grado, \{V. H.\} and D. Promeneur and Agans, \{K. N.\} and Lazaro, \{G. G.\} and V. Borisevich and Deer, \{D. J.\} and A. Luckay and M. Egan and Dimitrov, \{A. S.\} and B. Small and Broder, \{C. C.\} and Cross, \{R. W.\} and S. Hamm and Geisbert, \{T. W.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = dec,

doi = "10.1038/s41541-024-01036-2",

language = "English (US)",

volume = "9",

journal = "npj Vaccines",

issn = "2059-0105",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - Establishing an immune correlate of protection for Nipah virus in nonhuman primates

AU - Leyva-Grado, V. H.

AU - Promeneur, D.

AU - Agans, K. N.

AU - Lazaro, G. G.

AU - Borisevich, V.

AU - Deer, D. J.

AU - Luckay, A.

AU - Egan, M.

AU - Dimitrov, A. S.

AU - Small, B.

AU - Broder, C. C.

AU - Cross, R. W.

AU - Hamm, S.

AU - Geisbert, T. W.

PY - 2024/12

Y1 - 2024/12

N2 - The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

AB - The limited but recurrent outbreaks of the zoonotic Nipah virus (NiV) infection in humans, its high fatality rate, and the potential virus transmission from human to human make NiV a concerning threat with pandemic potential. There are no licensed vaccines to prevent infection and disease. A recombinant Hendra virus soluble G glycoprotein vaccine (HeV-sG-V) candidate was recently tested in a Phase I clinical trial. Because NiV outbreaks are sporadic, and with a few cases, licensing will likely require an alternate regulatory licensing pathway. Therefore, determining a reliable vaccine correlate of protection (CoP) will be critical. We assessed the immune responses elicited by HeV-sG-V in African Green monkeys and its relationship with protection from a NiV challenge. Data revealed values of specific binding and neutralizing antibody titers that predicted survival and allowed us to establish a mechanistic CoP for NiV Bangladesh and Malaysia strains.

UR - https://www.scopus.com/pages/publications/85212407844

UR - https://www.scopus.com/inward/citedby.url?scp=85212407844&partnerID=8YFLogxK

U2 - 10.1038/s41541-024-01036-2

DO - 10.1038/s41541-024-01036-2

M3 - Article

C2 - 39702562

AN - SCOPUS:85212407844

SN - 2059-0105

VL - 9

JO - npj Vaccines

JF - npj Vaccines

IS - 1

M1 - 244

ER -

Establishing an immune correlate of protection for Nipah virus in nonhuman primates

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this